NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
Clinical Trials
53 trialsNCT05862285 2026-03-13
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
NCT07079631 2026-03-06
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
BioNTech SE
Phase 1/2 Recruiting
NCT07024784 2026-03-04
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
Phase 2 Recruiting
NCT06252649 2026-02-27
CodeBreaK 301
Amgen
Phase 3 Recruiting
NCT05445778 2026-02-23
GLORIOSA
AbbVie
Phase 3 Recruiting
NCT05647122 2026-02-20
EGRET
AstraZeneca
Phase 1 Recruiting
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03148418 2026-01-13
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05112965 2026-01-07
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07277270 2026-01-07
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Recruiting
NCT06107413 2025-12-12
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
AbbVie
Phase 2 Active not recruiting
NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
NCT06906341 2025-10-22
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
Phase 2 Recruiting
NCT06796907 2025-10-14
BEHOLD-2
GlaxoSmithKline
Phase 1/2 Recruiting
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT06232902 2024-12-18
A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers
Qilu Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT06496971 2024-11-14
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Phase 3 Recruiting
NCT02848443 2024-07-25
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
Servier
Phase 1 Completed
NCT06329570 2024-03-26
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Not yet recruiting
NCT02753127 2023-11-15
CanStem303C
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04446416 2023-09-06
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Phase NA Completed
NCT02759588 2023-01-05
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
Phase 1/2 Completed
NCT03082209 2022-12-09
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
AbbVie
Phase 1 Completed
NCT02810457 2022-03-10
AVANA
Centus Biotherapeutics Limited
Phase 3 Completed
NCT03368859 2021-02-09
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
AbbVie
Phase 2 Terminated
NCT01588184 2020-11-05
An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
Hoffmann-La Roche
Phase 4 Completed
NCT01633970 2020-10-08
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01514123 2020-09-17
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors
Circadian Technologies Ltd.
Phase 1 Completed
NCT01498328 2020-02-17
ReACT
Celldex Therapeutics
Phase 2 Completed
NCT01274624 2018-12-19
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Oncolytics Biotech
Phase 1 Completed
NCT00115765 2018-10-17
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Amgen
Phase 3 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT01705002 2018-07-10
Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.
Lipomedix Pharmaceuticals Inc.
Phase 1 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT00992121 2017-11-13
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
GlaxoSmithKline
Phase 1 Completed
NCT00480831 2017-05-18
A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)
Genentech, Inc.
Phase 2 Completed
NCT00705874 2016-07-21
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Progen Pharmaceuticals
Phase 1 Completed
NCT00809133 2016-03-14
Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT00653939 2015-02-09
FALCON
Mateon Therapeutics
Phase 2 Completed
NCT00448136 2015-01-22
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.
Hoffmann-La Roche
Phase 2 Completed
NCT01193595 2014-12-03
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT02031991 2014-08-15
A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)
Pfizer
Phase 1 Completed
NCT00109239 2014-06-18
A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer
Genentech, Inc.
Phase 3 Completed
NCT00109226 2014-04-08
A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Genentech, Inc.
Phase 2 Completed
NCT00109057 2013-06-21
An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT00666692 2012-04-27
A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)
Abbott
Phase 1 Completed
NCT00395434 2011-10-31
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
Mateon Therapeutics
Phase 1 Completed